<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7707449</journal-id>
<journal-id journal-id-type="pubmed-jr-id">656</journal-id>
<journal-id journal-id-type="nlm-ta">Ann Neurol</journal-id>
<journal-id journal-id-type="iso-abbrev">Ann. Neurol.</journal-id>
<journal-title-group>
<journal-title>Annals of neurology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0364-5134</issn>
<issn pub-type="epub">1531-8249</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28165634</article-id>
<article-id pub-id-type="pmc">6171340</article-id>
<article-id pub-id-type="doi">10.1002/ana.24886</article-id>
<article-id pub-id-type="manuscript">NIHMS869130</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Pharmacogenetics of Antiepileptic Drug Efficacy in Childhood Absence Epilepsy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Glauser</surname>
<given-names>Tracy A.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Holland</surname>
<given-names>Katherine</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>O’Brien</surname>
<given-names>Valerie P.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Keddache</surname>
<given-names>Mehdi</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martin</surname>
<given-names>Lisa J.</given-names>
</name>
<degrees>Ph.D.</degrees>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Clark</surname>
<given-names>Peggy O.</given-names>
</name>
<degrees>DNP, PPCNP-BC</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cnaan</surname>
<given-names>Avital</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dlugos</surname>
<given-names>Dennis</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hirtz</surname>
<given-names>Deborah G</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shinnar</surname>
<given-names>Shlomo</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Grabowski</surname>
<given-names>Gregory</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<on-behalf-of>for the Childhood Absence Epilepsy Study Group</on-behalf-of>
</contrib-group>
<aff id="A1">
<label>1</label>Comprehensive Epilepsy Center, Division of Neurology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA and the University of Cincinnati College of Medicine, Cincinnati, Ohio, USA</aff>
<aff id="A2">
<label>2</label>Division of Human Genetics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA and the University of Cincinnati College of Medicine, Cincinnati, Ohio, USA</aff>
<aff id="A3">
<label>3</label>Division of Biostatistics and Study Methodology, Children’s National Health System, Washington, D.C</aff>
<aff id="A4">
<label>4</label>Division of Neurology, The Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania</aff>
<aff id="A5">
<label>5</label>National Institute of Neurological Disorders and Stroke, Bethesda, Maryland</aff>
<aff id="A6">
<label>6</label>Division of Neurology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, New York</aff>
<author-notes>
<corresp id="FN1">Corresponding author: Tracy A. Glauser, M.D., Comprehensive Epilepsy Center, Division of Neurology, MLC# 2015, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229. Phone: 513-636-7314, Fax: 513-636-1888. <email>tracy.glauser@cchmc.org</email></corresp>
<fn fn-type="COI-statement" id="FN3">
<p>CONFLICTS OF INTEREST</p>
<p>Dr. Glauser, Dr. Holland, Ms. O’Brien, Dr. Keddache, Dr. Martin, Dr. Clark, Dr. Cnaan, Dr. Dlugos, Dr. Hirtz, Dr. Shinnar and Dr. Grabowskihave nothing to disclose.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>18</day>
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>04</day>
<month>10</month>
<year>2018</year>
</pub-date>
<volume>81</volume>
<issue>3</issue>
<fpage>444</fpage>
<lpage>453</lpage>
<!--elocation-id from pubmed: 10.1002/ana.24886-->
<abstract>
<sec id="S1">
<title>Objective</title>
<p id="P1">Determine if common polymorphisms in CACNA1G, CACNA1H, CACNA1I, and ABCB1 are associated with differential short term seizure outcome in Childhood Absence Epilepsy (CAE).</p>
</sec>
<sec id="S2">
<title>Methods</title>
<p id="P2">446CAEchildren in a randomized double blind trial of ethosuximide, lamotrigine and valproate had short term seizure outcome determined. Associations between polymorphisms (minor allele frequency ≥15%)in four genes andseizure outcomes were assessed. <italic>In vitro</italic> electrophysiology on transfected CACNA1H channels determined impact of one variant on T-type calcium channel responsiveness to ethosuximide.</p>
</sec>
<sec id="S3">
<title>Results</title>
<p id="P3">80% (357/446) of subjects had informative short term seizure status (242 seizure free, 115 not seizure free). In ethosuximide subjects, two polymorphisms (CACNA1Hrs61734410/P640L, CACNA1I rs3747178) appeared more commonly among not seizure free participants (p=0.011; Odds Ratio(OR):2.63; 95% Confidence limits(CL):1.25–5.56, p=0.026; OR:2.38; 95%CL:1.11–5.00). In lamotrigine subjects, one ABCB1 missense polymorphism (rs2032582/S893A, p=0.015; OR:2.22; 95%CL:1.16–4.17) was more common in not seizure free participants, two CACNA1H polymorphisms (rs2753326, rs2753325) were more common in seizure free participants (p=0.038; OR:0.52; 95%CL:0.28–0.96). In valproate subjects, no common polymorphisms associated with seizure status. <italic>In vitro</italic> electrophysiological studies showed no effect of the P640L polymorphism on channel physiology in ethosuximide’s absence. Ethosuximide’s effect on rate of decay of Ca<sub>V</sub>3.2was significantly less for P640L channel compared to wild type channel.</p>
</sec>
<sec id="S4">
<title>Interpretation</title>
<p id="P4">Four T-type calcium channel variants and one ABCB1 transporter variant were associated with differential drug response in CAE. The <italic>in vivo</italic>P640L variant’s ethosuximide effect was confirmed by <italic>in vitro</italic> electrophysiological studies. This suggests genetic variation plays a role in differential CAE drug response.</p>
</sec>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>